-- Results Presented Today at the American Heart Association (AHA) Scientific Sessions 2023 and Simultaneously Published in the European Heart Journal Open -- DUBLIN, Ireland and BRIDGEWATER, N.J., ...
O’Brien et al. report that the combination of casirivimab and imdevimab (REGEN-COV) reduced the risk of symptomatic Covid-19 by 81.4% among persons exposed to SARS-CoV-2. 1 However, we question the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results